Oscar Bukstein, MD, MPH

Associate Psychiatrist-in-Chief; Vice Chair of Psychiatry; Director (Interim), Child & Adolescent Psychiatry Fellowship

Member of the Faculty (Harvard Medical School)

    Contact: 617-919-6954
  • Fax: 617-730-0428

“I treat my patients and their families as I would want my family to be treated.”

Medical Services

Specialties

  • Child and Adolescent Psychiatry
  • Addiction Psychiatry

Departments

  • Psychiatry

Languages

  • English

Programs

  • Outpatient Psychiatry
To schedule an appointment: Call 617-919-6954

Experience and Education

Education

Medical Degree

University of Texas Medical Branch, 1983

Galveston, TX

Internship

Western Psychiatric Institute and Clinic, 1983-1984

Pittsburgh, PA

Residency

Western Psychiatric Institute and Clinic, University of Pittsburgh, 1984-1988

Pittsburgh, PA

Fellowship

Western Psychiatric Institute and Clinic, University of Pittsburgh, 1984-1988

Pittsburgh, PA

Professional History

Prior to coming to Boston Children’s Hospital (BCH) in March 2016, Dr. Bukstein spent several years in Houston, Texas at the University of Texas (UT) Health Science Center in Houston where he was Professor of Psychiatry and Chief of the Division of Child and Adolescent Psychiatry and at DePelchin Children’s Center where he was Medical Director. He attended medical school at the University of Texas Medical Branch in Galveston and has a master’s degree in public health from the UT- Houston. He is board certified in psychiatry, and child and adolescent psychiatry and has over 30 years of practice experience with particular clinical and research expertise in treating youth with substance use disorders, and other disruptive behavior disorders. Dr. Bukstein has a substantial academic record, having authored or co-authored over 150 papers, chapters, or books and has received funding by the National Institute of Mental Health, the National Institute on Drug Abuse, the National Institute of Alcohol Abuse and Alcoholism, and the National Institute on Child Health and Human Development.

He spent 28 years at the Western Psychiatric Institute and Clinic (WPIC) and the University of Pittsburgh School of Medicine where achieved the rank of Professor of Psychiatry. He is presently co-chair of the Committee on Quality Issues, the component of the American Academy of Child and Adolescent Psychiatry that develops clinical practice guidelines for professionals treating children and adolescents with psychiatric disorders. 

Publications

Publications powered by Harvard Catalyst Profiles
  1. Gadow KD, Brown NV, Arnold LE, Buchan-Page KA, Bukstein OG, Butter E, Farmer CA, Findling RL, Kolko DJ, Molina BS, Rice RR, Schneider J, Aman MG. Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. J Am Acad Child Adolesc Psychiatry. 2016 Jun; 55(6):469-78.
  2. Arnold LE, Gadow KD, Farmer CA, Findling RL, Bukstein O, Molina BS, Brown NV, Li X, Rundberg-Rivera EV, Bangalore S, Buchan-Page K, Hurt EA, Rice R, McNamara NK, Aman MG. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):203-12.
  3. Farmer CA, Brown NV, Gadow KD, Arnold LE, Kolko DG, Findling RL, Molina BS, Buchan-Page KA, Rice RR, Bangalore SS, Bukstein O, Rundberg-Rivera EV, McNamara N, Aman MG. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):213-24.
  4. Rundberg-Rivera EV, Townsend LD, Schneider J, Farmer CA, Molina BB, Findling RL, Gadow KD, Bukstein OG, Arnold LE, Kolko DJ, Buchan-Page KA, McNamara NK, Michel C, Austin A, Kipp H, Rice RR, Aman MG. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):225-33.
  5. Kaat A, Farmer C, Gadow K, Findling RL, Bukstein O, Arnold LE, Bangalore S, McNamara N, Aman M. Factor Validity of a Proactive and Reactive Aggression Rating Scale. J Child Fam Stud. 2015 Sep 1; 24(9):2734-2744.
  6. Cutler AJ, Brams M, Bukstein O, Mattingly G, McBurnett K, White C, Rubin J. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2014 Oct; 53(10):1092-101.
  7. Gadow KD, Arnold LE, Molina BS, Findling RL, Bukstein OG, Brown NV, McNamara NK, Rundberg-Rivera EV, Li X, Kipp HL, Schneider J, Farmer CA, Baker JL, Sprafkin J, Rice RR, Bangalore SS, Butter EM, Buchan-Page KA, Hurt EA, Austin AB, Grondhuis SN, Aman MG. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. J Am Acad Child Adolesc Psychiatry. 2014 Sep; 53(9):948-959.e1.
  8. Goldstein BI, Goldstein TR, Collinger KA, Axelson DA, Bukstein OG, Birmaher B, Miklowitz DJ. Treatment development and feasibility study of family-focused treatment for adolescents with bipolar disorder and comorbid substance use disorders. J Psychiatr Pract. 2014 May; 20(3):237-48.
  9. Kolko DJ, Lindhiem O, Hart J, Bukstein OG. Evaluation of a booster intervention three years after acute treatment for early-onset disruptive behavior disorders. J Abnorm Child Psychol. 2014; 42(3):383-98.
  10. Aman MG, Bukstein OG, Gadow KD, Arnold LE, Molina BS, McNamara NK, Rundberg-Rivera EV, Li X, Kipp H, Schneider J, Butter EM, Baker J, Sprafkin J, Rice RR, Bangalore SS, Farmer CA, Austin AB, Buchan-Page KA, Brown NV, Hurt EA, Grondhuis SN, Findling RL. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014 Jan; 53(1):47-60.e1.
  11. Show all
  12. Bukstein OG. Personality-targeted interventions delivered by teachers may be effective at reducing alcohol use. Evid Based Ment Health. 2013 Nov; 16(4):100.
  13. Pearson DA, Santos CW, Aman MG, Arnold LE, Casat CD, Mansour R, Lane DM, Loveland KA, Bukstein OG, Jerger SW, Factor P, Vanwoerden S, Perez E, Cleveland LA. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol. 2013 Jun; 23(5):337-51.
  14. Bukstein OG, Head J. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 2012 Oct; 13(15):2207-13.
  15. Bukstein OG. Taking note of over-the-counter remedies for adolescents with cannabis dependence. Am J Psychiatry. 2012 Aug; 169(8):771-3.
  16. Bukstein OG. Attention deficit hyperactivity disorder and substance use disorders. Curr Top Behav Neurosci. 2012; 9:145-72.
  17. Kraus LJ, Thomas CR, Bukstein OG, Walter HJ, Benson RS, Chrisman A, Farchione TR, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S, Ptakowski KK, Medicus J. Practice parameter for child and adolescent forensic evaluations. J Am Acad Child Adolesc Psychiatry. 2011 Dec; 50(12):1299-312.
  18. Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K, Youcha S. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012 Jan; 51(1):74-85.e2.
  19. Farmer CA, Arnold LE, Bukstein OG, Findling RL, Gadow KD, Li X, Butter EM, Aman MG. The treatment of severe child aggression (TOSCA) study: Design challenges. Child Adolesc Psychiatry Ment Health. 2011 Nov 10; 5(1):36.
  20. Demidovich M, Kolko DJ, Bukstein OG, Hart J. Medication refusal in children with oppositional defiant disorder or conduct disorder and comorbid attention-deficit/hyperactivity disorder: medication history and clinical correlates. J Child Adolesc Psychopharmacol. 2011 Feb; 21(1):57-66.
  21. Dorn LD, Kolko DJ, Shenk CE, Susman EJ, Bukstein O. Influence of treatment for disruptive behavior disorders on adrenal and gonadal hormones in youth. J Clin Child Adolesc Psychol. 2011; 40(4):562-71.
  22. Bukstein OG. Clinical practice guidelines for attention-deficit/hyperactivity disorder: a review. Postgrad Med. 2010 Sep; 122(5):69-77.
  23. Bukstein OG, Horner MS. Management of the adolescent with substance use disorders and comorbid psychopathology. Child Adolesc Psychiatr Clin N Am. 2010 Jul; 19(3):609-23.
  24. Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, Wood DS, Brown SJ. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010 Nov 1; 112(1-2):39-45.
  25. Cohen JA, Bukstein O, Walter H, Benson SR, Chrisman A, Farchione TR, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S, Medicus J. Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. J Am Acad Child Adolesc Psychiatry. 2010 Apr; 49(4):414-30.
  26. Bukstein OG, Arnold LE, Landgraf JM, Hodgkins P. Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc Psychiatry Ment Health. 2009; 3(1):39.
  27. Goldstein BI, Bukstein OG. Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention. J Clin Psychiatry. 2010 Mar; 71(3):348-58.
  28. Cannon M, Pelham WH, Sallee FR, Palumbo DR, Bukstein O, Daviss WB. Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):511-7.
  29. Brent DA, Greenhill LL, Compton S, Emslie G, Wells K, Walkup JT, Vitiello B, Bukstein O, Stanley B, Posner K, Kennard BD, Cwik MF, Wagner A, Coffey B, March JS, Riddle M, Goldstein T, Curry J, Barnett S, Capasso L, Zelazny J, Hughes J, Shen S, Gugga SS, Turner JB. The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry. 2009 Oct; 48(10):987-96.
  30. Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther. 2009 Aug; 31(8):1844-55.
  31. Kolko DJ, Dorn LD, Bukstein OG, Pardini D, Holden EA, Hart J. Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up. J Abnorm Child Psychol. 2009 Jul; 37(5):591-609.
  32. Bukstein O. Substance use disorders and ADHD. CNS Spectr. 2009 Jul; 14(7 Suppl 6):10-1; discussion 13-4.
  33. Bukstein OG. Transdermal methylphenidate system: old wine in a new bottle. Expert Opin Drug Metab Toxicol. 2009 Jun; 5(6):661-5.
  34. Kelly TM, Donovan JE, Chung T, Bukstein OG, Cornelius JR. Brief screens for detecting alcohol use disorder among 18-20 year old young adults in emergency departments: Comparing AUDIT-C, CRAFFT, RAPS4-QF, FAST, RUFT-Cut, and DSM-IV 2-Item Scale. Addict Behav. 2009 Aug; 34(8):668-74.
  35. DeMaso DR, Martini DR, Cahen LA, Bukstein O, Walter HJ, Benson S, Chrisman A, Farchione T, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S, Ptakowski KK, Medicus J. Practice parameter for the psychiatric assessment and management of physically ill children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009 Feb; 48(2):213-33.
  36. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Keshavan MS, Bukstein OG, Pettegrew JW. Evidence of developmental alterations in cortical and subcortical regions of children with attention-deficit/hyperactivity disorder: a multivoxel in vivo phosphorus 31 spectroscopy study. Arch Gen Psychiatry. 2008 Dec; 65(12):1419-28.
  37. Bukstein O. Substance use disorders in adolescents with attention-deficit/hyperactivity disorder. Adolesc Med State Art Rev. 2008 Aug; 19(2):242-53, viii.
  38. Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling RL. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009 Jan; 12(4):308-15.
  39. Szobot CM, Bukstein O. Attention deficit hyperactivity disorder and substance use disorders. Child Adolesc Psychiatr Clin N Am. 2008 Apr; 17(2):309-23, viii.
  40. Bukstein O. Substance abuse in patients with attention-deficit/hyperactivity disorder. Medscape J Med. 2008; 10(1):24.
  41. Molina BS, Flory K, Bukstein OG, Greiner AR, Baker JL, Krug V, Evans SW. Feasibility and preliminary efficacy of an after-school program for middle schoolers with ADHD: a randomized trial in a large public middle school. J Atten Disord. 2008 Nov; 12(3):207-17.
  42. Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008 Jan; 69(1):149-59.
  43. Birmaher B, Brent D, Bernet W, Bukstein O, Walter H, Benson RS, Chrisman A, Farchione T, Greenhill L, Hamilton J, Keable H, Kinlan J, Schoettle U, Stock S, Ptakowski KK, Medicus J. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007 Nov; 46(11):1503-26.
  44. Manos MJ, Tom-Revzon C, Bukstein OG, Crismon ML. Changes and challenges: managing ADHD in a fast-paced world. J Manag Care Pharm. 2007 Nov; 13(9 Suppl B):S2-S13; quiz S14-S16.
  45. March JS, Szatmari P, Bukstein O, Chrisman A, Kondo D, Hamilton JD, Kremer CM, Kratochvil CJ. AACAP 2005 Research Forum: speeding the adoption of evidence-based practice in pediatric psychiatry. J Am Acad Child Adolesc Psychiatry. 2007 Sep; 46(9):1098-110.
  46. Szobot CM, Rohde LA, Bukstein O, Molina BS, Martins C, Ruaro P, Pechansky F. Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case-control study. Addiction. 2007 Jul; 102(7):1122-30.
  47. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Pettegrew JW, Keshavan MS, Bukstein OG. Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo 31P spectroscopy study. Psychiatry Res. 2006 Dec 1; 148(2-3):217-21.
  48. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006 Jun; 16(3):351-6.
  49. Bukstein OG. Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders. Expert Rev Neurother. 2006 Apr; 6(4):541-9.
  50. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006 Jan; 160(1):82-90.
  51. Bukstein OG, Cornelius J, Trunzo AC, Kelly TM, Wood DS. Clinical predictors of treatment in a population of adolescents with alcohol use disorders. Addict Behav. 2005 Oct; 30(9):1663-73.
  52. Kelly TM, Donovan JE, Cornelius JR, Bukstein OG, Delbridge TR, Kinnane JM. Alcohol use disorder symptoms and risk-taking behavior as predictors of alcohol-related medical events among young adults treated in emergency departments. Addict Behav. 2005 Oct; 30(9):1674-89.
  53. Cornelius JR, Clark DB, Bukstein OG, Birmaher B, Salloum IM, Brown SA. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. Addict Behav. 2005 Oct; 30(9):1824-33.
  54. Bukstein OG, Bernet W, Arnold V, Beitchman J, Shaw J, Benson RS, Kinlan J, McClellan J, Stock S, Ptakowski KK. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry. 2005 Jun; 44(6):609-21.
  55. Cornelius JR, Clark DB, Bukstein OG, Kelly TM, Salloum IM, Wood DS. Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: a 3-year follow-up study. Addict Behav. 2005 May; 30(4):807-14.
  56. Chacko A, Pelham WE, Gnagy EM, Greiner A, Vallano G, Bukstein O, Rancurello M. Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2005 Mar; 44(3):249-57.
  57. Cornelius JR, Clark DB, Bukstein OG, Salloum IM. Treatment of co-occurring alcohol, drug, and psychiatric disorders. Recent Dev Alcohol. 2005; 17:349-65.
  58. Fritz G, Rockney R, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, Kroeger Ptakowski K. Practice parameter for the assessment and treatment of children and adolescents with enuresis. J Am Acad Child Adolesc Psychiatry. 2004 Dec; 43(12):1540-50.
  59. Ghaziuddin N, Kutcher SP, Knapp P, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, Kroeger Ptakowski K. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry. 2004 Dec; 43(12):1521-39.
  60. Bukstein OG, Winters K. Salient variables for treatment research of adolescent alcohol and other substance use disorders. Addiction. 2004 Nov; 99 Suppl 2:23-37.
  61. Cornelius JR, Maisto SA, Martin CS, Bukstein OG, Salloum IM, Daley DC, Wood DS, Clark DB. Major depression associated with earlier alcohol relapse in treated teens with AUD. Addict Behav. 2004 Jul; 29(5):1035-8.
  62. Bukstein OG. Satisfaction with treatment for attention-deficit/hyperactivity disorder. Am J Manag Care. 2004 Jul; 10(4 Suppl):S107-16.
  63. Cornelius JR, Clark DB, Salloum IM, Bukstein OG, Kelly TM. Interventions in suicidal alcoholics. Alcohol Clin Exp Res. 2004 May; 28(5 Suppl):89S-96S.
  64. Cornelius JR, Bukstein OG, Salloum IM, Kelly TM, Wood DS, Clark DB. Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation. J Child Adolesc Psychopharmacol. 2004; 14(1):33-8.
  65. Clark DB, Wood DS, Cornelius JR, Bukstein OG, Martin CS. Clinical practices in the pharmacological treatment of comorbid psychopathology in adolescents with alcohol use disorders. J Subst Abuse Treat. 2003 Dec; 25(4):293-5.
  66. Kelly TM, Donovan JE, Cornelius JR, Bukstein OG, Delbridge TR, Clark DB. Psychiatric disorders among older adolescents treated in emergency departments on weekends: a comparison with a matched community sample. J Stud Alcohol. 2003 Sep; 64(5):616-22.
  67. Bukstein OG. Once-daily atomoxetine may reduce attention deficit hyperactivity disorder symptoms in children and adolescents. Evid Based Ment Health. 2003 May; 6(2):42.
  68. Cornelius JR, Bukstein O, Salloum I, Clark D. Alcohol and psychiatric comorbidity. Recent Dev Alcohol. 2003; 16:361-74.
  69. Molina BS, Bukstein OG, Lynch KG. Attention-deficit/hyperactivity disorder and conduct disorder symptomatology in adolescents with alcohol use disorder. Psychol Addict Behav. 2002 Jun; 16(2):161-4.
  70. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002 Feb; 41(2 Suppl):26S-49S.
  71. Masters KJ, Bellonci C, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S. Practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions, with special reference to seclusion and restraint. J Am Acad Child Adolesc Psychiatry. 2002 Feb; 41(2 Suppl):4S-25S.
  72. Clark DB, Bukstein O, Cornelius J. Alcohol use disorders in adolescents: epidemiology, diagnosis, psychosocial interventions, and pharmacological treatment. Paediatr Drugs. 2002; 4(8):493-502.
  73. Vitiello B, Brent DA, Greenhill LL, Emslie G, Wells K, Walkup JT, Stanley B, Bukstein O, Kennard BD, Compton S, Coffey B, Cwik MF, Posner K, Wagner A, March JS, Riddle M, Goldstein T, Curry J, Capasso L, Mayes T, Shen S, Gugga SS, Turner JB, Barnett S, Zelazny J. Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry. 2009 Oct; 48(10):997-1004.
  74. Dorn LD, Kolko DJ, Susman EJ, Huang B, Stein H, Music E, Bukstein OG. Salivary gonadal and adrenal hormone differences in boys and girls with and without disruptive behavior disorders: Contextual variants. Biol Psychol. 2009 Apr; 81(1):31-9.
  75. Cornelius JR, Douaihy A, Bukstein OG, Daley DC, Wood SD, Kelly TM, Salloum IM. Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents. Addict Behav. 2011 Aug; 36(8):843-8.
  76. Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):180-8.
  77. Cornelius JR, Bukstein OG, Wood DS, Kirisci L, Douaihy A, Clark DB. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav. 2009 Oct; 34(10):905-9.
  78. Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, Palumbo D, Harris P, Sallee FR. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):189-98.
  79. Marshal MP, Friedman MS, Stall R, King KM, Miles J, Gold MA, Bukstein OG, Morse JQ. Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction. 2008 Apr; 103(4):546-56.
  80. Shenk CE, Dorn LD, Kolko DJ, Susman EJ, Noll JG, Bukstein OG. Predicting Treatment Response for Oppositional Defiant and Conduct Disorder Using Pre-treatment Adrenal and Gonadal Hormones. J Child Fam Stud. 2012 Dec; 21(6):973-981.
To schedule an appointment: Call 617-919-6954

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close